
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
This medicine has provisional approval in Australia to treat COVID-19 in adults who are at increased risk of progression to hospitalisation or death. This approval has been granted on the basis of short-term efficacy and safety data. Evidence of efficacy and safety from ongoing trials continues to be gathered and assessed.
PAXLOVID™ (nirmatrelvir/ritonavir)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Paxlovid™ Quick Finder
*9AM-5PM (AEST) Monday to Friday
Connect with Pfizer Medical Information regarding your medical question.